Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
about
Adjuvant Therapy for completely resected Stage II Colon CancerAdjuvant Therapy for completely resected stage II Colon CancerPrognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.Adjuvant chemotherapy in colon cancer: what is the evidence?Current stage-specific chemotherapeutic options in colon cancer.Current status of adjuvant therapy for colon cancer.Recent approaches to identifying biomarkers for high-risk stage II colon cancer.Conventional adverse features do not predict response to adjuvant chemotherapy in stage II colon cancer.Immunohistochemical analysis of vascular density and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic factors.Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome.Cytokeratin 20 and vascular endothelial growth factor as molecular markers in Egyptian patients with colorectal cancer.Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection.Comparison of blood neoangiogenesis and lymphatic vascularization in colorectal adenomas from patients with and without concomitant colorectal cancer.8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients.Prognostic factors for survival after curative resection of Dukes' B colonic cancer.Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
P2860
Q24242231-A651AA47-1858-4DE6-A31D-58FEAABAC465Q24244432-5E15DA33-F058-4BF4-808D-4F858A1253B1Q26830362-C8F5240A-3C30-45C1-9765-5BDFC44B6A01Q31106341-2872081A-3C86-4E20-8AB7-2BD81267C697Q33434559-E1925C74-DFF5-45AB-B781-1A4516D38715Q34631210-C7BECEF3-714D-405C-B9C4-82C336AFD88CQ35072225-44914388-8E37-49D5-BD10-826342A46EDDQ36235576-86F9DB11-4135-4BF2-8B23-A08E42301253Q37077225-091E7E23-A38D-477C-AA3F-CCBC7E8C3C81Q38041974-2E0E9603-739F-4180-B464-B318650DECE8Q38162282-701ABD6E-39FE-48AB-ABE8-D8308C56B2BEQ38412668-A8933D7D-945D-4756-81D5-197CEA9D1D25Q38452399-C75369BC-9153-49E7-87CA-4C9706CB5958Q38883781-B1DDE831-30D4-4F67-BC19-A2E61A736D2CQ43452895-B58403E8-2741-497B-9172-FE5AD341377EQ44344925-EC0ED8C2-9116-40FD-8F51-840E5039D6DCQ47733549-02AB7A31-C0A2-4AA1-AA59-DF08B5758065Q50853288-9122553A-B028-4684-8F4E-95DEC65A42E4Q52846761-6BBB16D7-409F-436F-8E96-675BB3DCE50FQ52930698-F1304A66-A183-4706-9237-9A2334B58FB3
P2860
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@ast
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@en
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@nl
type
label
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@ast
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@en
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@nl
prefLabel
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@ast
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@en
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@nl
P1433
P1476
Should Dukes' B patients receive adjuvant therapy? A statistical perspective.
@en
P2093
P356
10.1016/S0093-7754(01)90247-7
P433
P577
2001-02-01T00:00:00Z